ClinicalTrials.gg
TerminatedNCT03530293Updated May 17, 2022Results posted

Safety and Efficacy of NBI-98854 in Pediatric Subjects With Tourette Syndrome

A Phase 2 interventional study of Valbenazine and Placebo oral capsule in Tourette Syndrome, sponsored by Neurocrine Biosciences. Terminated at 49 sites in 2 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2022-05-17.

Sponsored by Neurocrine Biosciences · Phase 2, Interventional, and Treatment

Why this study was terminated
Futility

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
81
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 139 studies in Tourette Syndrome with a site in United States — 20 open to participants now, 24 under way, 1 of them phase 3. Tourette Syndrome · United States.

Enrollment
33rd of 105
81 · median 33
Started
2018
with 11 others
Phase 2
26 of 139
4 open now
Registered
87th of 139
by date
Lead sponsor
8 of 139
Neurocrine Biosciences

Among the 139 studies in Tourette Syndrome with a site in United States, this one is the 33rd largest by enrollment of the 105 interventional ones that give a count, is one of 12 that started in 2018, is one of 26 in phase 2, and was the 87th registered.

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

Browse Tourette Syndrome studies →

Open to participants now

20 of the 139 studies in Tourette Syndrome with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Tourette Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 2, double-blind, placebo-controlled, randomized withdrawal study to evaluate the safety and maintenance of efficacy of an optimized once-daily (qd) dose of NBI-98854 in pediatric subjects with TS.

03

Conditions studied

  • Tourette Syndrome

Browse trials for

04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a clinical diagnosis of Tourette Syndrome (TS)
  2. Have at least moderate tic severity
  3. Have TS symptoms that impair school, occupational, and/or social function
  4. If using maintenance medication(s) for TS or TS spectrum diagnoses (e.g. obsessive-compulsive disorder [OCD], Attention-Deficit Hyperactivity Disorder [ADHD]), be on stable doses
  5. Be in good general health
  6. Adolescent subjects (12 to 17 years of age) must have a negative urine drug screen for amphetamines, barbiturates, benzodiazepine, phencyclidine, cocaine, opiates, or cannabinoids and a negative alcohol screen
  7. Subjects of who do not practice total abstinence must agree to use hormonal or two forms of nonhormonal (dual contraception) consistently during the screening, treatment and follow-up periods of the study

Exclusion criteria

Exclusion Criteria:

  1. Have an active, unstable medical condition within 1 month prior to screening
  2. Have a known history of long syndrome or cardiac arrhythmia
  3. Have a known history of neuroleptic malignant syndrome
  4. Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed)
  5. Have an allergy, , or intolerance to VMAT2 inhibitors
  6. Have a blood loss ≥250 mL or donated blood within 30 days prior to screening
  7. Have a known history of substance dependence, substance (drug) or alcohol abuse
  8. Have a significant risk of suicidal or violent behavior
  9. Have initiated Comprehensive Behavioral Intervention for Tics (CBIT) during the screening period or at baseline or plan to initiate CBIT during the study
  10. Have received an drug within 30 days before screening or plan to use an investigational drug (other than NBI-98854) during the study
  11. Have previously participated in an NBI-98854 clinical study, except for NBI-98854-1403 or NBI-98854-1501.
  12. Have , , or
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
81 participants (actual)

Study arms

  • Experimental
    Pre-randomization Valbenazine

    Participants received valbenazine once daily for up to 12 weeks, depending on if and when randomization occured. The starting dose was 20 mg for participants \<50 kg at baseline and 40 mg for participants ≥50 kg at baseline, and could be escalated in increments of 20 mg every 2 weeks to a maximum of 60 mg for participants \<50 kg and 80 mg for participants ≥50 kg to achieve an optimal dose of valbenazine for each participant.

    Drug: Valbenazine

  • Placebo comparator
    Randomized Placebo

    Participants received placebo (matching valbenazine) once daily from randomization (Week 8, 10, or 12) through Week 36. Randomization into this arm occurred after treatment with valbenazine once daily through randomization.

    Drug: Placebo oral capsule

  • Experimental
    Randomized Valbenazine

    Participants received their optimized dose of valbenazine once daily from randomization (Week 8, 10, or 12) through Week 36. Randomization into this arm occurred after treatment with valbenazine once daily through randomization.

    Drug: Valbenazine

Interventions

  • vesicular monoamine transporter 2 (VMAT2) inhibitor

    Also known as: NBI-98854

  • DrugPlacebo oral capsule

    non-active dosage form

06

What researchers measure

Primary outcomes

  1. Time to Loss of Treatment Response

    Loss of treatment response during the withdrawal period was defined as: 2 consecutive visits with 1) an increase in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS) of greater than 35% or 7 points from the randomized withdrawal period baseline and 2) an increase in CGI-Tics-Severity score of ≥2 points from the randomized withdrawal period baseline; or discontinuation due to lack of efficacy or a treatment-emergent adverse event (TEAE) of worsening of tics. Median (lower and upper quartiles) Kaplan-Meier estimates for the time to loss of treatment response were not able to be calculated because of the low incidence of loss of treatment response events.

    Time frame: Randomization (Week 8, 10 or 12) through Week 36

Secondary outcomes

  1. Change From Randomization Baseline to the 8 Weeks Post-randomization Timepoint in the YGTSS TTS

    The YGTSS is designed to rate the overall severity of motor and phonic tic symptoms across a range of dimensions: number, frequency, intensity, complexity, and interference. The YGTSS was administered by the investigator (or qualified designee) using a computer-based structured clinical interview. The TTS is the sum of the 5 motor tic items and the 5 phonic (vocal) tic items and ranges from 0 to 50, with higher scores representing greater severity. Least-squares mean were estimated using a mixed-effects model for repeated measures.

    Time frame: Randomization Baseline (Week 8, 10 or 12); 8 weeks post-randomization

  2. Change From Randomization Baseline to the Week 36 Visit in the YGTSS TTS

    The YGTSS is designed to rate the overall severity of motor and phonic tic symptoms across a range of dimensions: number, frequency, intensity, complexity, and interference. The YGTSS was administered by the investigator (or qualified designee) using a computer-based structured clinical interview. The TTS is the sum of the 5 motor tic items and the 5 phonic (vocal) tic items and ranges from 0 to 50, with higher scores representing greater severity.

    Time frame: Randomization Baseline (Week 8, 10 or 12); Week 36

  3. Change From Randomization Baseline to the 8 Weeks Post-randomization Timepoint in the CGI-Tics-Severity Score

    The CGI-Tics-Severity scale is used to assess overall severity on a 7-point scale. Each of the CGI-Tics-Severity response categories was assigned a numerical score as follows: 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill patient.

    Time frame: Randomization Baseline (Week 8, 10 or 12); 8 weeks post-randomization

  4. Change From Randomization Baseline to the Week 36 Visit in the CGI-Tics-Severity Score

    The CGI-Tics-Severity scale is used to assess overall severity on a 7-point scale. Each of the CGI-Tics-Severity response categories was assigned a numerical score as follows: 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill patient.

    Time frame: Randomization Baseline (Week 8, 10 or 12); Week 36

07

Results

Posted May 17, 2022

Participant flow

Up to 180 male and female pediatric subjects between 6 and 17 years of age (inclusive) with a DSM-IV or -V diagnosis of TS were planned to be enrolled. A total of 81 subjects were enrolled. The first and last participants were enrolled on April 17 2018 and May 7 2019, respectively.

Pre-randomization
Participant flow — Pre-randomization
MilestonePre-randomization ValbenazineRandomized PlaceboRandomized Valbenazine
Started8100
Safety analysis set8000
Completed5700
Not completed2400
Withdrew: Adverse event1200
Withdrew: Protocol violation200
Withdrew: Study terminated by sponsor500
Withdrew: Withdrawal by subject500
Randomized Withdrawal Period / Follow-up
Participant flow — Randomized Withdrawal Period / Follow-up
MilestonePre-randomization ValbenazineRandomized PlaceboRandomized Valbenazine
Started02626
Completed099
Not completed01717
Withdrew: Adverse event024
Withdrew: Protocol violation001
Withdrew: Withdrawal by subject032
Withdrew: Lack of efficacy020
Withdrew: Study terminated by sponsor01010

Outcome measures

PrimaryTime to Loss of Treatment Response

Loss of treatment response during the withdrawal period was defined as: 2 consecutive visits with 1) an increase in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS) of greater than 35% or 7 points from the randomized withdrawal period baseline and 2) an increase in CGI-Tics-Severity score of ≥2 points from the randomized withdrawal period baseline; or discontinuation due to lack of efficacy or a treatment-emergent adverse event (TEAE) of worsening of tics. Median (lower and upper quartiles) Kaplan-Meier estimates for the time to loss of treatment response were not able to be calculated because of the low incidence of loss of treatment response events.

Time frame:
Randomization (Week 8, 10 or 12) through Week 36
Reported as:
Median · Days
Time to Loss of Treatment Response
DaysRandomized PlaceboRandomized Valbenazine
Time to Loss of Treatment ResponseNA (NA to NA)NA (NA to NA)
SecondaryChange From Randomization Baseline to the 8 Weeks Post-randomization Timepoint in the YGTSS TTS

The YGTSS is designed to rate the overall severity of motor and phonic tic symptoms across a range of dimensions: number, frequency, intensity, complexity, and interference. The YGTSS was administered by the investigator (or qualified designee) using a computer-based structured clinical interview. The TTS is the sum of the 5 motor tic items and the 5 phonic (vocal) tic items and ranges from 0 to 50, with higher scores representing greater severity. Least-squares mean were estimated using a mixed-effects model for repeated measures.

Time frame:
Randomization Baseline (Week 8, 10 or 12); 8 weeks post-randomization
Reported as:
Least squares mean · units on a scale
Change From Randomization Baseline to the 8 Weeks Post-randomization Timepoint in the YGTSS TTS
units on a scaleRandomized PlaceboRandomized Valbenazine
Change From Randomization Baseline to the 8 Weeks Post-randomization Timepoint in the YGTSS TTS3.8 ± 1.6-1.0 ± 1.7
SecondaryChange From Randomization Baseline to the Week 36 Visit in the YGTSS TTS

The YGTSS is designed to rate the overall severity of motor and phonic tic symptoms across a range of dimensions: number, frequency, intensity, complexity, and interference. The YGTSS was administered by the investigator (or qualified designee) using a computer-based structured clinical interview. The TTS is the sum of the 5 motor tic items and the 5 phonic (vocal) tic items and ranges from 0 to 50, with higher scores representing greater severity.

Time frame:
Randomization Baseline (Week 8, 10 or 12); Week 36
Reported as:
Mean · units on a scale
Change From Randomization Baseline to the Week 36 Visit in the YGTSS TTS
units on a scaleRandomized PlaceboRandomized Valbenazine
Change From Randomization Baseline to the Week 36 Visit in the YGTSS TTS0.6 ± 12.060.1 ± 8.21
SecondaryChange From Randomization Baseline to the 8 Weeks Post-randomization Timepoint in the CGI-Tics-Severity Score

The CGI-Tics-Severity scale is used to assess overall severity on a 7-point scale. Each of the CGI-Tics-Severity response categories was assigned a numerical score as follows: 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill patient.

Time frame:
Randomization Baseline (Week 8, 10 or 12); 8 weeks post-randomization
Reported as:
Least squares mean · units on a scale
Change From Randomization Baseline to the 8 Weeks Post-randomization Timepoint in the CGI-Tics-Severity Score
units on a scaleRandomized PlaceboRandomized Valbenazine
Change From Randomization Baseline to the 8 Weeks Post-randomization Timepoint in the CGI-Tics-Severity Score0.7 ± 0.2-0.1 ± 0.2
SecondaryChange From Randomization Baseline to the Week 36 Visit in the CGI-Tics-Severity Score

The CGI-Tics-Severity scale is used to assess overall severity on a 7-point scale. Each of the CGI-Tics-Severity response categories was assigned a numerical score as follows: 1 = Normal, not at all ill; 2 = Borderline ill; 3 = Mildly ill; 4 = Moderately ill; 5 = Markedly ill; 6 = Severely ill; 7 = Among the most extremely ill patient.

Time frame:
Randomization Baseline (Week 8, 10 or 12); Week 36
Reported as:
Mean · units on a scale
Change From Randomization Baseline to the Week 36 Visit in the CGI-Tics-Severity Score
units on a scaleRandomized PlaceboRandomized Valbenazine
Change From Randomization Baseline to the Week 36 Visit in the CGI-Tics-Severity Score0.1 ± 0.780.2 ± 1.30

Adverse events

Collected over Pre-randomization valbenazine group: from baseline up to randomization (Week 8, 10 or 12) or end of participation in subjects who did not randomize, up to 16 weeks. Randomized placebo and valbenazine groups: from randomization (Week 8, 10 or 12) up to Week 40. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pre-randomization Valbenazine0/80 (0%)1/80 (1.3%)41/80 (51.3%)
Randomized Placebo0/26 (0%)2/26 (7.7%)12/26 (46.2%)
Randomized Valbenazine0/26 (0%)2/26 (7.7%)14/26 (53.8%)
Most frequent serious events
Most frequent serious events
EventPre-randomization ValbenazineRandomized PlaceboRandomized Valbenazine
AkathisiaNervous system disorders0/800/261/26
TicPsychiatric disorders0/800/261/26
Obsessive-compulsive disorderPsychiatric disorders0/801/260/26
Tourette's disorderCongenital, familial and genetic disorders0/801/260/26
Enterovirus infectionInfections and infestations1/800/260/26
Most frequent other events
Showing 10 of 19
Most frequent other events
EventPre-randomization ValbenazineRandomized PlaceboRandomized Valbenazine
SomnolenceNervous system disorders20/800/261/26
NauseaGastrointestinal disorders4/801/264/26
IrritabilityGeneral disorders6/804/264/26
AnxietyPsychiatric disorders1/804/260/26
FatigueGeneral disorders10/801/260/26
VomitingGastrointestinal disorders4/800/263/26
MyalgiaMusculoskeletal and connective tissue disorders0/801/263/26
HeadacheNervous system disorders9/803/262/26
Nasal congestionRespiratory, thoracic and mediastinal disorders7/801/261/26
Gastroenteritis viralInfections and infestations0/802/261/26

Baseline characteristics

The full analysis set includes all subjects who were randomized to a treatment group and had at least one post-randomization visit where loss of treatment response was able to be assessed.

Age, Continuous
Age, Continuous(years)Randomized PlaceboRandomized ValbenazineTotal
Mean12.7 ± 2.712.8 ± 3.112.8 ± 2.9
Sex: Female, Male
Sex: Female, Male(Participants)Randomized PlaceboRandomized ValbenazineTotal
Female527
Male212445
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Randomized PlaceboRandomized ValbenazineTotal
Hispanic or Latino8614
Not Hispanic or Latino182038
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Randomized PlaceboRandomized ValbenazineTotal
American Indian or Alaska Native000
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American202
White222446
More than one race011
Unknown or Not Reported112
08

Study locations

49 sites
  • Neuricrine Clinical Site
    Sun City, Arizona 85351, United States
  • Neurocrine Clinical Site
    Little Rock, Arkansas 72205, United States
  • Neurocrine Clinical Site
    Rogers, Arkansas 72758, United States
  • Neurocrine Clinical Site
    Anaheim, California 92805, United States
  • Neurocrine Clinical Site
    Fullerton, California 92835, United States
  • Neurocrine Clinical Site
    San Diego, California 92108, United States
  • Neurocrine Clinical Site
    Santa Ana, California 92705, United States
  • Neurocrine Clinical Site
    Pueblo, Colorado 81003, United States
  • Neurocrine Clinical Site
    Stamford, Connecticut 06905, United States
  • Neurocrine Clinical Site
    Washington, District of Columbia 22207, United States
  • Neurocrine Clinical Site
    Gulf Breeze, Florida 32561, United States
  • Neurocrine Clinical Site
    Hialeah, Florida 33012, United States
  • Neurocrine Clinical Site
    Miami, Florida 33125, United States
  • Neurocrine Clinical Site
    Miami, Florida 33136, United States
  • Neurocrine Clinical Site
    North Miami, Florida 33161, United States
  • Neurocrine Clinical Site
    Orlando, Florida 32803, United States
  • Neurocrine Clinical Site
    Palmetto Bay, Florida 33157, United States
  • Neurocrine Clinical Site
    Saint Petersburg, Florida 33701, United States
  • Neurocrine Clinical Site
    Spring Hill, Florida 34609, United States
  • Neurocrine Clinical Site
    Tallahassee, Florida 32308, United States
  • Neurocrine Clinical Site
    Atlanta, Georgia 30338, United States
  • Neurocrine Clinical Site
    Fayetteville, Georgia 30214, United States
  • Neurocrine Clinical Site
    Savannah, Georgia 31406, United States
  • Neurocrine Clinical Site
    Chicago, Illinois 60634, United States
  • Neurocrine Clinical Site
    South Bend, Indiana 46617, United States
  • Neurocrine Clinical Site
    Boston, Massachusetts 02114, United States
  • Neurocrine Clinical Site
    Ann Arbor, Michigan 48015, United States
  • Neurocrine Clinical Site
    Bloomfield Hills, Michigan 48302, United States
  • Neurocrine Clinical Site
    West Bloomfield, Michigan 48322, United States
  • Neurocrine Clinical Site
    Lincoln, Nebraska 68526, United States
  • Neurocrine Clinical Site
    Nashua, New Hampshire 03060, United States
  • Neurocrine Clinical Site
    Cherry Hill, New Jersey 08002, United States
  • Neurocrine Clinical Site
    Mount Arlington, New Jersey 07856, United States
  • Neurocrine Clinical Site
    New York, New York 10036, United States
  • Neurocrine Clinical Site
    S. Setauket, New York 11720, United States
  • Neurocrine Clinical Site
    Charlotte, North Carolina 29141, United States
  • Neurocrine Clinical Site
    Mason, Ohio 45040, United States
  • Neurocrine Clinical Site
    Oklahoma City, Oklahoma 73112, United States
  • Neurocrine Clinical Site
    Dallas, Texas 75243, United States
  • Neurocrine Clinical Site
    DeSoto, Texas 75115, United States
  • Neurocrine Clinical Site
    Houston, Texas 77030, United States
  • Neurocrine Clinical Site
    Houston, Texas 77058, United States
  • Neurocrine Clinical Site
    Irving, Texas 75062, United States
  • Neurocrine Clinical Site
    San Antonio, Texas 78249, United States
  • Neurocrine Clinical Site
    Charlottesville, Virginia 22903, United States
  • Neurocrine Clinical Site
    Bothell, Washington 98011, United States
  • Neurocrine Clinical Site
    Everett, Washington 98201, United States
  • Neurocrine Clinical Site
    Spokane, Washington 99202, United States
  • Neurocrine Clinical Site
    San Juan, 00926, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Jul 2019, 14 months.

Results were first posted in May 2022, 2 years 10 months after primary completion. A results delay was requested in Jan 2020.

How these figures are worked out, and which studies are left out of them.

Registered
May 8, 2018
First posted
May 21, 2018
StartActual
Apr 17, 2018
Primary completionActual
Jul 16, 2019
CompletionActual
Jul 16, 2019
Results delay requested
Jan 30, 2020
Results first posted
May 17, 2022
Last update
May 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03530293
Responsible party
Sponsor
First posted
May 21, 2018
Start date
Apr 17, 2018
Primary completion
Jul 16, 2019
Completion
Jul 16, 2019
Results posted
May 17, 2022
Last update
May 17, 2022

Study contacts

Clinical Development Lead
study director · Neurocrine Biosciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Valbenazine

Start the discussion